Global Bioanalytical Testing Services Market Assessment, By Test Type [Pharmacokinetic Testing, Pharmacodynamic Testing, Biomarker Testing, Virology Testing, Serology Testing, Cell-based Assays, Others], By Molecule [Small Molecule, Large Molecule], By Application [Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Research and Academic Institutes, Others], By End-user [Hospitals and Specialty Clinics, Ambulatory Surgical Centers, Others], By Region, Opportunities and Forecast, 2018-2032F

Global bioanalytical testing services market is projected to witness a CAGR of 10.69% during the forecast period 2025-2032, growing from USD 4.04 billion in 2024 to USD 9.10 billion in 2032.

Global Bioanalytical Testing Services Market: Trends, Growth, and Future Outlook

Global bioanalytical testing services market is projected to witness a CAGR of 10.69% during the forecast period 2025-2032, growing from USD 4.04 billion in 2024 to USD 9.10 billion in 2032. Growing R&amp;D expenditure, rise in clinical trials, and demand for biologics and biosimilars augment the market's growth for bioanalytical testing services. This drives the demand for specialty testing services and enhances the trend of outsourcing; therefore, it improves technological advancement, which can collectively generate a strong market growth environment in the following years.
The rising cases of chronic diseases like diabetes, cancer, and cardiovascular disorders fuel the requirement for bioanalytical testing services. As per WHO, non-communicable diseases account for 74% of all global deaths annually. This increased burden demands a requirement for advanced drug development and precision medicine, wherein bioanalytical testing would be of immense importance. Such services provide proper and accurate therapeutic efficacy and safety assessment, thereby contributing to innovation in pharmaceuticals and regulatory compliance that satisfies increased healthcare demands around the globe.
Furthermore, CROs are expanding their global reach by opening state-of-the-art bioanalytical labs and strategic partnerships. These activities enhance the services offered, streamline drug development processes, and ensure that these services comply with regional regulations. This focused expansion unlocks new growth opportunities as the demand for localized and specialized bioanalytical testing increases. In August 2024, BioAgilytix Labs, LLC, recently opened the expanded 360biolabs laboratory in Melbourne, Australia. This cutting-edge facility provides a broad range of bioanalytical services such as LC-MS/MS, molecular testing, biomarker analysis, flow cytometry, large molecule PK and immunogenicity, virology, and central lab services, all performed in a quality-assured environment. This expansion supports global pharmaceutical and biotech clients, driving significant growth opportunities in the market.
<h2>Increasing R&amp;D Expenditure Boosts Market Demand</h2>
Increasing R&amp;D spending is also propelling the demand for bioanalytical testing in the market. As pharmaceutical companies invest more in R&amp;D, clinical trials and drug development are rising, demanding more comprehensive bioanalytical testing services. Furthermore, pharmaceuticals' improvement and acceleration of R&amp;D manufacturing units to enhance efficiency and make drug development more streamlined involves implementing advanced technologies and automation, for which specialized bioanalytical testing is required to ensure quality and safety. This concern about biologics and biosimilars also leads to more compatibility studies, stability testing, and protein analysis, further driving the bioanalytical testing market. In November 2024,&nbsp;AstraZeneca PLC made a USD 3.5 billion investment to accelerate R&amp;D and manufacturing in the U.S. This expansion includes a new R&amp;D center in Massachusetts and a next-gen biologics facility in Maryland. These improvements boost the development of leading-edge therapies and drive considerable growth opportunities in the market. With higher R&amp;D investment comes greater demand for all-inclusive bioanalytical services for new pharmaceutical development and approval.
<h2>Rising Number of Clinical Trials Support Market Expansion</h2>
The rise in clinical trials has greatly propelled the growth of the bioanalytical testing services market. The volume of biological samples is increasing, and the complexity of the trials involving biologics and personalized medicines require advanced bioanalytical methods because of their tailored treatment approaches and complex molecular structures. Therefore, the demand for bioanalytical testing increases. Moreover, outsourcing bioanalytical testing, which focuses on biopharmaceuticals, including gene therapies and biosimilars, strengthens the market by improving efficiency and boosting investment in advanced technologies by pharmaceutical companies. Additionally, various collaborations ensure comprehensive clinical trial services in several companies to ease all drug development processes. All these collaborations positively influence the market through data accuracy, regulation compliance, and acceleration of new pharmaceutical approvals for its growth. In March 2024, EPNextS, Inc. and Frontage Laboratories, Inc. collaborated to improve early-phase clinical trials in Japan. This collaboration is meant to overcome the delay in drug availability due to strict regulations and complicated procedures. Combining their expertise, they are trying to streamline drug development and enhance market growth opportunities through improved access to innovative therapies.
<h2>Pharmaceuticals and Biopharmaceutical Companies Account for Significant Share of the Market</h2>
The pharmaceutical and biopharmaceutical firms are the most prominent end-users in this market for bioanalytical testing services, focusing on developing drugs and, hence, for severe stringent regulations. Such companies rely on bioanalytical testing for early-phase development, pharmacokinetics, and clinical laboratory testing. This has been one of the significant growth drivers for outsourcing such activities for cost savings and high-end expertise. Demand for personalized medicine and biologics is continuously growing and will continue to drive this trend. This trend further followed the increasing demand for personalized medicine and biologics.
Many biopharma and biotechnology companies have extended their partnership with CROs for bioanalytical services, which has accelerated biological drug development. This recent surge in outsourcing reflects the strategic shift to streamline operations and meets the rising demand for innovative therapies. For instance, in May 2024, BioAgilytix Labs, LLC, and BBI Solutions OEM Limited partnered to streamline bioanalytical testing. This partnership aligns reagent development with assay creation, making testing easier for pharma and biopharma sponsors. This streamlined approach accelerates the market entry of innovative therapies.
<h2>North America Holds Major Market Share</h2>
North America dominates the bioanalytical testing services market because of innovation and strong infrastructure. The region has well-established and developed facilities. In particular, the United States has many pharmaceutical and biotechnology companies, which creates a high demand for bioanalytical testing services. Also, strict FDA regulations in the region ensure that pharmaceutical companies maintain high-quality testing standards, which demand bioanalytical testing services. Thus, major companies are expanding their testing service portfolios to meet the increasing demand. In August 2024, SGS Soci&eacute;t&eacute; G&eacute;n&eacute;rale de Surveillance SA launched its new bioanalytical testing services in North America with the help of Agilex Biolabs Pty Ltd. This expansion provides more extensive, high-quality testing solutions and enhances market growth through comprehensive support for clinical trials and drug development.
Moreover, the growing need for advanced testing methods, such as immunoassays and electrophoresis, will further drive the market growth in the region. The region's strength is further emphasized due to its significant R&amp;D investment and focus on new and innovative biopharmaceutical drug development, which enables it to set the pace of excellence in bioanalytical testing.
<a href="https://www.marketsandata.com/industry-reports/global-bioanalytical-testing-services-market/sample-request">Download Free Sample Report</a>
<h2>Future Market Scenario (2025-2032F)</h2>
The bioanalytical testing services market is anticipated to grow with the rise of R&amp;D expenditure, biopharmaceutical industry expansion, technological advancements, severe regulatory compliance, and outsourcing trends that increase demand during the forecast period.
Strategic collaborations between pharmaceutical companies and CROs will expand the scope of high-end bioanalytical testing solutions to address varied pharmaceutical and biopharma requirements and present new growth opportunities. For example, in October 2024, Synexa Life Sciences BV enhanced its bio-analysis capabilities by acquiring Alderley Analytical Ltd. The acquisition strengthens Synexa's growth strategy and enhances its biomarker and bioanalytical assay capability, including DNA, RNA, protein, cell, and tissue analysis.
Additionally, key players are expanding their services to invest more in the advancements that support market expansion. In September 2024, Laboratory Corporation of America Holdings expanded its molecular bioanalytical laboratory in Indiana. The expansion enhanced LabCorp&rsquo;s global capacity to deliver advanced therapies more quickly to patients. Expanding bioanalytical capabilities supports biopharmaceutical companies, which drives future market growth and accelerates the availability of life-saving treatments.
Report Scope
&ldquo;Bioanalytical Testing Services&nbsp;Market Assessment, Opportunities and Forecast, 2018-2032F&rdquo;,&nbsp;is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the global bioanalytical testing services market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.
<table>
<tbody>
<tr>
<td width="301">
Report Attribute
</td>
<td width="301">
Details
</td>
</tr>
<tr>
<td width="301">
Base Year of the Analysis
</td>
<td width="301">
2024
</td>
</tr>
<tr>
<td width="301">
Historical Period
</td>
<td width="301">
2018-2023
</td>
</tr>
<tr>
<td width="301">
Forecast Period
</td>
<td width="301">
2025-2032
</td>
</tr>
<tr>
<td width="301">
Projected Growth Rate
</td>
<td width="301">
CAGR of 10.69% between 2025 and 2032
</td>
</tr>
<tr>
<td width="301">
Revenue Forecast in 2032
</td>
<td width="301">
USD 9.10 billion
</td>
</tr>
<tr>
<td width="301">
Segments Covered
</td>
<td width="301">
Test Type, Molecule, Application, End-user
</td>
</tr>
<tr>
<td width="301">
Regions Covered
</td>
<td width="301">
North America, Europe, South America, Asia-Pacific, Middle East and Africa
</td>
</tr>
<tr>
<td width="301">
Key Companies Profile
</td>
<td width="301">
WuXi AppTec Co., Ltd., Eurofins Scientific SE, Charles River Laboratories International, Inc., ICON Plc, Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, SGS Soci&eacute;t&eacute; G&eacute;n&eacute;rale de Surveillance SA, Intertek Group plc, Frontage Laboratories, Inc., BioAgilytix Labs, LLC
</td>
</tr>
<tr>
<td width="301">
Customization Scope
</td>
<td width="301">
15% free report customization with purchase
</td>
</tr>
<tr>
<td width="301">
Pricing and Purchase Options
</td>
<td width="301">
Avail the customized purchase options to fulfill your precise research needs
</td>
</tr>
<tr>
<td width="301">
Delivery Format
</td>
<td width="301">
PDF and Excel through email (subject to the license purchased)
</td>
</tr>
</tbody>
</table>
In the report,&nbsp;global bioanalytical testing services market&nbsp;has been segmented into the following categories:&nbsp;
<ul>
<li>By&nbsp;Test&nbsp;Type
<ul>
<li>Pharmacokinetic Testing</li>
<li>Pharmacodynamic Testing</li>
<li>Biomarker Testing</li>
<li>Virology Testing</li>
<li>Serology testing</li>
<li>Cell-based Assays</li>
<li>Other Test Types</li>
</ul>
</li>
<li>By&nbsp;Molecule
<ul>
<li>Small Molecule</li>
<li>Large Molecule</li>
</ul>
</li>
<li>By Application
<ul>
<li>Oncology</li>
<li>Neurology</li>
<li>Cardiology</li>
<li>Infectious Diseases</li>
<li>Others</li>
</ul>
</li>
<li>By End-user
<ul>
<li>Pharmaceutical and Biotechnology Companies</li>
<li>Contract Research Organizations (CROs)</li>
<li>Research and Academic Institutes</li>
<li>Others</li>
</ul>
</li>
<li>By Region
<ul>
<li>North America</li>
<li>Europe</li>
<li>Asia-Pacific</li>
<li>South America</li>
<li>Middle East and Africa</li>
</ul>
</li>
</ul>
Key Players Landscape and Outlook
Market players aim to grow by expanding services and adopting new technologies. They enter into strategic partnerships, mergers, and acquisitions to improve their offerings and benefit from the technology available to enhance their global market position.
In October 2024, Eurofins Scientific SE acquired clinical diagnostics operations for the German company SYNLAB International GmbH in Spain. The deal increases the company's commitment to delivering the best testing services worldwide. Eurofins Scientific SE considers itself the trusted, sophisticated partner of private and public sectors involved in health services, private hospitals, and insurance companies, ensuring excellent testing facilities.
In January 2024, Frontage Laboratories, Inc. expanded its European footprint by acquiring the Bioanalytical and Drug Metabolism &amp; Pharmacokinetics businesses of Accelera S.r.l (part of an NMS Group S.p.A). The acquisition is one of the most significant steps forward for the company from its base in Italy, focusing on providing the best quality and cutting-edge services to clients.
Key Players Operating in Global Bioanalytical Testing Services&nbsp;Market are:
<ul>
<li>WuXi AppTec Co., Ltd.&nbsp;</li>
<li>Eurofins Scientific SE</li>
<li>Charles River Laboratories International, Inc.</li>
<li>ICON Plc</li>
<li>Thermo Fisher Scientific Inc.</li>
<li>Laboratory Corporation of America Holdings</li>
<li>SGS Soci&eacute;t&eacute; G&eacute;n&eacute;rale de Surveillance SA</li>
<li>Intertek Group plc</li>
<li>Frontage Laboratories, Inc.</li>
<li>BioAgilytix Labs, LLC</li>
</ul>
Markets and Data&rsquo;s reports answer the following questions:
<ul>
<li>What is the current and future market size of the product/service in question globally or specific to different countries?</li>
<li>How are the markets divided into different product/service segments and the market size and growth of each segment?</li>
<li>What is the market potential of different product segments and their investment case?</li>
<li>How are the markets predicted to develop in the future and what factors will drive or inhibit growth?</li>
<li>What is the business environment and regulatory landscape specific to the product/service?</li>
</ul>
If you can't find what you're searching for or have any custom requirements for&nbsp;global bioanalytical testing services&nbsp;market, you may approach our team at&nbsp;<a href="mailto:info@marketsandata.com">info@marketsandata.com</a>

Global Bioanalytical Testing Services Market Assessment, Opportunities and Forecast, 2018-2032F

The market growth of bioanalytical testing services is boosted by increased R&D expenditure, rising clinical trials, expansion of biopharmaceuticals, technological advancements, stringent regulatory requirements, and outsourcing trends, driving demand for comprehensive and efficient bioanalytical testing solutions during the forecast period.

FAQs

Industry Reports

Blogs

Case Studies

Industry News

Press Release

Infographics